Literature DB >> 26209528

Breast cancer screening and diagnosis in the 21st century within the U.K.

Philip J Murray1, Glynis Wivell2, Erika Denton2.   

Abstract

In the UK, breast cancer represents the most commonly diagnosed cancer in females and carries with it a significant morbidity and mortality. An established national screening programme is in place to identify those with the disease at an early stage in order to optimise treatment and prognosis. This article provides an overview for the non-breast specialist clinician whose practice regularly deals with women who may be the subject of the screening programme. It outlines the diagnostic methods employed in the screening programme, the controversies that have surrounded it and the evolving technologies that will improve detection and diagnostic accuracy.
© The Author(s) 2015.

Entities:  

Keywords:  Breast cancer; breast screening programme; diagnostics; radiology

Mesh:

Year:  2015        PMID: 26209528     DOI: 10.1177/2053369115594954

Source DB:  PubMed          Journal:  Post Reprod Health        ISSN: 2053-3691


  4 in total

1.  A common trap of diagnostic tests : Disease prevalence and positive predictive value.

Authors:  Johannes Mischlinger; Eva Schernhammer
Journal:  Wien Klin Wochenschr       Date:  2017-04-26       Impact factor: 1.704

2.  Role of short-term follow-up magnetic resonance imaging in the detection of post-operative residual breast cancer.

Authors:  Yili Zhang; Hongwen Du
Journal:  Mol Clin Oncol       Date:  2016-06-09

3.  A Micro CT Study in Patients with Breast Microcalcifications Using a Mathematical Algorithm to Assess 3D Structure.

Authors:  David Kenkel; Zsuzsanna Varga; Heike Heuer; Konstantin J Dedes; Nicole Berger; Lukas Filli; Andreas Boss
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

4.  Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis.

Authors:  Jing Chen; Jingjing Sun; Qunfeng Wang; Yanze Du; Jie Cheng; Juan Yi; Bei Xie; Suya Jin; Gang Chen; Lina Wang; Xiaoyuan Wang; Hulai Wei
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.